Danaher DHR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales by Business | ||||||
| Biotechnology | $7.48B+9.2% | $7.29B+7.9% | $7.13B+7.2% | $6.98B+4.9% | $6.85B+0.2% | |
| Diagnostics | $9.91B+2.1% | $9.94B+1.6% | $9.86B-0.1% | $9.76B0.0% | $9.71B-0.2% | |
| Life Sciences | $7.39B+1.7% | $7.33B+0.1% | $7.28B+0.7% | $7.27B+1.7% | $7.26B+1.2% | |
| Sales by Product | ||||||
| Nonrecurring revenue | $4.44B+0.1% | $4.44B-1.5% | $4.36B-3.0% | $4.35B-6.8% | $4.43B-9.9% | |
| Recurring revenue | $20.34B+4.9% | $20.13B+3.9% | $19.91B+3.4% | $19.67B+4.0% | $19.39B+3.0% | |
| Sales by Geography | ||||||
| High-growth markets | $7.11B+3.5% | $7.02B+2.2% | $6.91B+1.5% | $6.87B+0.5% | $6.87B-1.6% | |
| North America | $10.25B+0.1% | $10.36B+0.6% | $10.37B+0.6% | $10.25B+0.2% | $10.25B+1.0% | |
| Other developed markets | $1.26B+2.4% | $1.25B-0.1% | $1.25B+0.2% | $1.23B-1.2% | $1.23B-1.7% | |
| Western Europe | $6.16B+12.5% | $5.94B+8.8% | $5.74B+6.7% | $5.66B+7.7% | $5.48B+2.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
